| Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions AEG Osman, MW Deininger Blood reviews 49, 100825, 2021 | 105 | 2021 |
| Treatment of acute promyelocytic leukemia in adults AEG Osman, J Anderson, JE Churpek, TN Christ, E Curran, LA Godley, ... Journal of oncology practice 14 (11), 649-657, 2018 | 62 | 2018 |
| Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations S Feurstein, A Adegunsoye, D Mojsilovic, R Vij, AH West DePersia, ... Blood Advances 4 (19), 4873-4886, 2020 | 32 | 2020 |
| Hereditary myelodysplastic syndrome and acute myeloid leukemia: diagnosis, questions, and controversies IJ Akpan, AEG Osman, MW Drazer, LA Godley Current Hematologic Malignancy Reports 13, 426-434, 2018 | 27 | 2018 |
| When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)? AEWG Osman Hematology 2021 (1), 399-404, 2021 | 16 | 2021 |
| The impact of the fecal microbiome on cancer immunotherapy AEG Osman, JJ Luke BioDrugs 33, 1-7, 2019 | 8 | 2019 |
| Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones AEG Osman, N Mencia-Trinchant, C Saygin, L Moma, A Kim, G Housman, ... Blood Advances 7 (9), 1910-1914, 2023 | 6 | 2023 |
| The characteristics and prognosis of patients with clonal cytopenias of undetermined significance, including cancer and therapy-related clonal cytopenias Z Xie, A Smith, RS Komrokji, N Al Ali, AA Patel, C Saygin, AM Zeidan, ... Blood 140 (Supplement 1), 2887-2890, 2022 | 6 | 2022 |
| Characteristics and clinical outcome of patients with clonal cytopenias of undetermined significance: a large retrospective multi-center international study Z Xie, MC Hyun, RS Komrokji, AM Zeidan, YF Madanat, JF Zeidner, ... Blood 138, 2158, 2021 | 6 | 2021 |
| Rheumatoid arthritis causing diffuse alveolar haemorrhage: a novel therapeutic approach A Osman, P Galiatsatos, S Bose, S Danoff Case Reports 2017, bcr-2017-220509, 2017 | 5 | 2017 |
| Sudden worsening of DRESS syndrome on tapering steroid dose with dramatic improvement on N-acetylcysteine and steroid dose escalation A Osman, W Ibrahim, I Khanjar, N Abdulla, R Eltahir, E Alhamoud Ibnosina Journal of Medicine and Biomedical Sciences 6 (02), 101-105, 2014 | 5 | 2014 |
| Involvement of Rho-associated coiled-coil containing kinase (ROCK) in BCR-ABL1 tyrosine kinase inhibitor cardiovascular toxicity B Yu, AEG Osman, N Sladojevic, N Prabhu, HC Tai, D Chen, G Perla, ... Cardio Oncology 4 (3), 371-383, 2022 | 4 | 2022 |
| Diagnostic challenge and clinical dilemma: the long reach of clonal hematopoiesis A Osman, JL Patel Clinical Chemistry 67 (8), 1062-1070, 2021 | 4 | 2021 |
| Change in IgHV mutational status of CLL suggests origin from multiple clones A Osman, CD Gocke, DE Gladstone Clinical Lymphoma Myeloma and Leukemia 17 (2), 97-99, 2017 | 4 | 2017 |
| The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors CE Wheeler, SS Coleman IV, R Hoyd, L Denko, CHF Chan, ... bioRxiv, 2023 | 3 | 2023 |
| Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: systematic literature review with case illustration DM Croci, NT Gamboa, AEG Osman, L Maese, M Mazur, EF Bisson, ... Clinical Neurology and Neurosurgery 212, 107064, 2022 | 3 | 2022 |
| ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic … A Osman, B Yu, N Glavin, TS Polonsky, JK Liao, RA Larson Blood 132, 1739, 2018 | 3 | 2018 |
| A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset C Wang, A Ma, Y Li, ME McNutt, S Zhang, J Zhu, R Hoyd, CE Wheeler, ... Cancer research communications 4 (2), 293-302, 2024 | 2 | 2024 |
| Germline predisposition to clonal hematopoiesis J Liu, AEG Osman, K Bolton, LA Godley Leukemia Research, 107344, 2023 | 2 | 2023 |
| Concerto (NCT04409639): a phase 2 trial of cobimetinib in newly diagnosed and HMA-treated CMML patients with RAS pathway mutations AB Patel, A Osman, TD Pomicter, SK Tantravahi, MW Deininger Blood 140 (Supplement 1), 4060-4061, 2022 | 2 | 2022 |
